Managing Anemia in Chronic Kidney Disease: Beyond Iron and ESAs
Iron therapy and erythropoiesis-stimulating agents are not always effective for anemia in patients with CKD. Nutritional interventions may be helpful in these cases.
Iron therapy and erythropoiesis-stimulating agents are not always effective for anemia in patients with CKD. Nutritional interventions may be helpful in these cases.
A nurse practitioner (NP) was sued after a patient was harmed because of a prescribing error.
February FDA approvals include treatments for geographic atrophy, proteinuria, tardive dyskinesia and chorea associated with Huntington disease, and anemia.
Daprodustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor.
Participants with total seafood n-3 PUFA level in highest vs lowest fifth had 13% lower risk for incident chronic kidney disease.
Results were consistent for patients with and without pre-existing chronic kidney disease.
Layered approach involves initially combining lifestyle interventions, self-management, and first-line pharmacotherapy.
Incidence lower in White patients vs Black, Hispanic, and indigenous populations.
A round up of studies suggests it is difficult to increase serum total 25-hydroxyvitamin D levels enough to effectively lower elevated parathyroid hormone (PTH) levels in overweight patients with chronic kidney disease.
Author reviews calciphylaxis incidence, risk factors, pathogenesis, differential diagnoses, and treatment.